Challenging the Treatment of Respiratory Viruses
We are a pioneering biotech company committed to the discovery of new antiviral treatments.
Developing Products with Lower Risk &
Higher Efficacy
As a company, TrippBio is dedicated to enhancing the healthcare treatment industry and changing lives across the globe. Our goal is to bring life-saving treatments to patients worldwide.
Our current product, PanCytoVir™, aims to:
- Lessen Disease Severity
- Block Virus Replication
- Reduce Hyper-Inflammation
Advanced Phases of Testing for Innovative PanCytoVir™ Drug
PanCytoVir™ has Highly Successful Covid 19 Phase 2 Clinical Trial and It has a both Antiviral and Anti-inflammatory features in one safe drug. Furthermore, the host response is instrumental in keeping this drug effective as the virus undergoes mutations. PanCytoVir benefits from method-of-use patent coverage.
Phase 2 Trial Results
In this phase 2 dose-ranging study, probenecid was associated with a potent, dose-dependent antiviral effect and a significant reduction in COVID-19-related symptoms in non-hospitalized patients who were mildly to moderately symptomatic with COVID-19. Considerable antiviral activity was observed, with a significant reduction in the time required to reach an undetectable SARS-CoV-2 viral load and a significant difference in the change from baseline in SARS-CoV-2 viral RNA concentrations.
Treatment for Emerging Respiratory Viruses
TrippBio focuses on developing innovative applications of existing drugs with low risk and high efficacy to treat viral pathogens like influenza, RSV, and COVID-19.
